The human ETS2 gene, a member of the ETS gene family, with sequence homology with the retroviral ets sequence of the avian erythroblastosis retrovirus E26 is located on chromosome 21. Molecular genetic analysis of Down syndrome (DS) patients with partial trisomy 21 allowed us to reinforce the supposition that ETS2 may be a gene of the minimal DS genetic region. It was originally proposed that a duplication of a portion of the DS region represents the genetic basis of Alzheimer disease, a condition associated also with DS.
ABSTRACT
The human ETS2 gene, a member of the ETS gene family, with sequence homology with the retroviral ets sequence of the avian erythroblastosis retrovirus E26 is located on chromosome 21 . Molecular genetic analysis of Down syndrome (DS) patients with partial trisomy 21 allowed us to reinforce the supposition that ETS2 may be a gene of the minimal DS genetic region. It was originally proposed that a duplication of a portion of the DS region represents the genetic basis of Alzheimer disease, a condition associated also with DS. No evidence of either rearrangements or duplications of ETS2 could be detected in DNA from fibroblasts and brain tissue of Alzheimer disease patients with either the sporadic or the familiar form ofthe disease. Thus, an altered ETS2 gene dosage does not seem to be a genetic cause or component of Alzheimer disease.
Two human diseases, Down syndrome (DS) and Alzheimer disease (AD), in some way interrelated (see below), represent a puzzle for geneticists. DS, is the most common inherited disease, occurring once in 1000 live births (1) . The majority of DS patients present one extra chromosome 21 (2) as a result of a nondisjunction event in one of the meiotic stages. Thus, for more than 20 years, the imbalance of the entire extra set of chromosome 21 genes has been thought to be the cause of the abnormal development, the dismorphic features, and the mental retardation observed in the disease (3) (4) (5) (6) . Few DS cases present with the trisomy ofjust a small portion of chromosome 21 . This allowed the definition that only the trisomy of the distal portion of the chromosome may be sufficient for generating the DS phenotype (7) (8) (9) (10) (11) (12) . In this region 20-100 genes may be present. We do not know if all or just a few of them are crucial for the appearance of the syndrome. Moreover, it is not clear whether the genes that cause the prenatal abnormal development of DS are the same genes that produce a number of postnatal abnormalities often developed by DS patients. Among these, the most commonly recorded anomalies are the high susceptibility to infections; the predisposition to leukemia in DS children; the premature aging; and the development of the neurological signs of AD (13, 14) . AD, a degenerative disorder of the central nervous system, is not limited to DS individuals. AD causes profound mental and physical disability and is the fourth leading cause of death among the population in middle to late adult life (15) . Two forms of AD are known: one rare familial form caused by an autosomal dominant gene defect and the most common sporadic form with unknown, possibly genetic, etiology. The occurrence of AD-like disease in the already mentally impaired DS patients originated the theory that the imbalance (trisomy?; deregulation?) of one or more genes of the DS minimal genetic region could be implicated in the origin ofAD (16) . The recent identification ofthe genetic locus causing the familial AD on chromosome 21q21 (17) , far outside the DS region, would not exclude the existence of other gene(s) for the sporadic form in other sites of chromosome 21 or on other chromosomes. Actually, the recent literature is rich in reports that implicate in sporadic AD "this or that" gene on chromosome 21. Scattered microduplications of the chromosome have been proposed as an explanation of increased gene dosage for the superoxide dismutase (SOD!) gene (18) , the protooncogene ETS2 (19, 20) , and the amyloid ,8-protein gene APP (21) as measured in the genome of AD patients. These findings prompted us to investigate this issue as far as the ETS2 gene is concerned. The human ETS2 gene, first identified in our laboratory (22) as a member of a family of genes related to the v-ets gene of the avian erythroblastosis retrovirus E26, is located on chromosome 21 (23, 24) and is highly conserved, being found from lower organisms, like Drosophila (25) and sea urchin (26) , to man (22) ; this gene codes for a nuclear 56-kDa protein (27) that might play a critical role in controlling some step of the signaling transduction pathway. Thus, ETS2, as other genes with homology with viral oncogenes, might well be instrumental in regulating cellular growth and differentiation as well as organismal development.
MATERIALS AND METHODS Patient Material. Fibroblasts from different patients with various chromosome aneuploidies (described in detail in Fig.  1 ) were analyzed. Cases T-1 and T-2 presented complete trisomy 21; C-1 (28, 29) , C-2 (30), C-3 (10), and C-4 (10) presented partial trisomy 21: C-5 (30), C-6 (31), and C-7 (31) presented partial monosomy 21; M-1 (32) and M-2 (33) presented complete monosomy 21. Seven fibroblast strains were derived from AD patients. Six (A-1 to A-6) were derived from familial AD patients. A-7 was derived from a sporadic AD patient ascertained at the autopsy. All fibroblast strains, including fibroblasts from two normal individuals, were cultured in minimal essential medium (MEM) containing 10% (vol/vol) fetal calf serum. Twenty brain specimens (A-8 to A-27), all from sporadic AD patients confirmed at autopsy, were also analyzed. (The AD specimens were obtained from the Brain Bank of the Douglas Hospital Research Center, Montreal, Canada.) Gene Dosage Analysis. Genomic DNA was extracted from cultured cells and brain specimens as described (34) . Aliquots of 10 ,ug of genomic DNA were digested with various restriction enzymes as indicated by the supplier (Boehringer Mannheim). Agarose gel electrophoresis, Southern blotting, hybridization, and stringency of the washing conditions have been described in detail elsewhere (34) . The probes used included a 1.0-kilobase (kb) genomic fragment of ETS2 (22) , a few chromosome 21 anonymous probes mapping proxiAbbreviations: DS, Down syndrome; AD, Alzheinier disease; RFLP, restriction fragment length polymorphism. tTo whom reprint requests should be addressed.
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Partial trisomy q22>qter
Partial trisomy q1 1>qter
Partial trisomy q21 >qter
Partial trisomy pter>q21
Partial monosomy q22>qter
Partial monosomy pter>q2105
Partial monosomies pter>pl3; q22>qter mally or distally to ETS2 (35, 36) , and a 0.45-kb anonymous DNA fragment mapping on chromosome 22 (N.S., unpublished data).
Allelic dosage was evaluated by visual inspection of the intensity of the allelic fragments detected by the polymorphic probes within the same lane of autoradiograms of Southern blots. Quantitative densitometric analysis was performed on autoradiograms of Southern blots containing both control (diploid) and test DNAs. The ratio between the hybridization signals of the EcoRI 3.8-kb fragment detected by the ETS2 probe and the EcoRI 3.2-kb fragment detected by the reference probe on chromosome 22 was calculated for each sample in the same Southern blot to correct for DNA loading. Southern blot filters were first hybridized to the ETS2 probe, freed of the probe, and hybridized to the reference 0.45-kb probe. The densitometric tracing of autoradiograms were performed with a laser LKB Ultroscan densitometer. The peak areas corresponding to each hybridization signal were calculated by electronic integration.
RESULTS
First we assessed whether ETS2 was always in three copies in the putative DS region by analyzing directly (DNA of DS cases C-1, C-2, and C-3) or indirectly (case C-6, brother of two DS patients) a few of these regions (Fig. 1) . We measured the ETS2 gene content in these patients' DNAs by t sing 1 2 , lanes 4 and 5), and only two alleles, Al A2, were observed in heterozygous AD fibroblasts (patients A-2 and A-5, respectively) (Fig. 2, lanes 9 and 10) . Brain DNAs from 20 patients with sporadic AD were also analyzed. Heterozygosity for Taq I ETS2 polymorphism was observed in 14 cases. A typical blot is shown in Fig. 3 , where one copy ofeach allele Al and A2 was detected in heterozygous patient DNAs (lanes 1 to 4). Our observations exclude the presence ofthree copies of ETS2 also in all the other 10 heterozygous patients we analyzed (data not shown). The overall RFLP analysis was indicative of (i) unequivocal association between three copies ofETS2 and the extra chromosome 21 material causing DS (37) . From this analysis it was possible to interpret the "probable" copy number ofETS2 gene in each case, except for two cases, C-6 and A-4 (this is the reason for the question mark), which had P values of 0.0002 and 0.0015, respectively. The entire set of 36 means was further examined by analysis of variance, followed by the Student-Newman-Keuls multiple comparison test at the 0.05 probability level (37) . This test identified a distinct set of three homogeneous test samples (M-1, M-2, and C-5) with mean ratios ranging from 0.524 to 0.624, which would be interpreted as having one copy of ETS2, and a second distinct set of five homogeneous test samples (T-1, T-2, C-1, C-2, and C-3) with mean ratios ranging from 1.407 to 1.516, which would be interpreted as having three copies of the gene (Fig. 4) . The means of the remaining 10 test samples fell in a middle ground, having ratios ranging from 0.909 to 1.180, the same approximate range as those containing all of the 18 controls obtained from two individuals. In the student-Newman-Keuls test, the difference between C-6 and its control no longer remained significant, thus leading to the interpretation of two ETS2 copies. However, the difference between A-4 and its control remained significant, although only marginally at the 0.05 probability level.
To complement the information obtained from densitometry, RFLP analysis using polymorphic chromosome 21 sequences, chosen for loci proximal or distal to ETS2 according to the genetic map (35, 36) , was also performed. In cases of heterozygosity for the alleles detected by these polymorphic probes, the analysis confirmed the disomy or detected by the ETS2 probe and the EcoRI 3.2-kb band of a reference probe on chromosome 22 was evaluated in five independent experiments for each test DNA and for each control (C) DNA. Test DNA (five lanes) and control DNA (five lanes) were compared in the same Southern blot. The mean, SD, and SEM were calculated for each test and control DNA on five ratio values. By using the t test, the probability (P) that the difference between the mean values of test and control samples would be due to chance was calculated and the probable number of ETS2 gene copies was deduced in each case, with the exception of subjects C-6 and A-4 (see question marks).
the trisomy of the regions adjacent to ETS2 (data not shown). For instance, in patient C-1 the trisomy for the region surrounding ETS2 was reaffirmed from the observation of the allelic ratio detected by the D21S23 probe distal to ETS2 (35) (Fig. 5, lane 1) , when compared to the heterozygous RFLP pattern of a complete trisomy 21 (lane 2) and a normal control (lane 3), respectively. In each patient the additional RFLP analysis helped to accept with confidence the conclusions relative to the ETS2 dosage deduced from quantitative densitometry-the obligate technique whenever there was a homozygous condition for this locus. DISCUSSION The supposition that ETS2 located at the 21q22 band (23, 24) might be an element of the putative DS genetic region (7) (8) (9) (10) (11) (12) is reinforced by the present findings. ETS2 was found in three copies in all the partial trisomies 21 associated with DS phenotype that we analyzed. In particular, ETS2 was found Genetics: Sacchi et al. Table 1 of the 18 patients and 18 matching controls (from two normal individuals) were examined by analysis of variance followed by the Student-Newman-Keuls multiple comparison test at the probability level of 0.05. The controls are marked by an asterisk (e.g., C-1* is the control of C-1). A set of 3 homogeneous test samples (M-1, M-2, and C-5) would be interpreted as having one ETS2 gene; a second distinct set of 5 test samples (T-1, T-2, C-1, C-2, and C-3) would be interpreted as having three copies of ETS2. The remaining 10 samples presented ratios in the approximate range containing all of the 18 control samples and would be interpreted as having two ETS2 gene copies.
in triplicate when the trisomic region was barely visible at the cytogenetic analysis, as in patient C-1. Recent reports claimed that an extra copy of the ETS2 gene was present in the DNA of AD patients. These reports, based on quantitative densitometry (19) and in situ hybridization (20) , were in line with the proposed hypothesis that trisomy of one (or more) gene(s) in the DS region could be the cause of AD (16) . On the contrary, the results of our analysis showed that two copies of ETS2 are commonly found in both familial and sporadic forms of AD. Even if the existence of genetic heterogeneity among various AD patients cannot be excluded, the most probable reason for the difference between our results and the results of other reports (19, 20) (43) .
The search for other genes that may be implicated in AD should not be restricted only to chromosome 21 . It has been proposed (44) that recently evolved genes responsible for the most elaborated regions of human brain may be the ones that when mutated or deregulated confer AD. According to this hypothesis, AD, which does not find a naturally occurring analog in animals (45) and has a predilection for the association neocortices, some parts of the hyppocampal formations, the nucleus basalis of Meynert, and the amygadala (44) is a "phylogenetic" disease. In view of this attractive hypothesis, it is more likely that genes generated through recent molecular evolution should contribute to AD. On this ground, ETS2 having features of a highly conserved gene should be extraneous to this pathology. Indeed, ETS2 is found from invertebrates (25, 26) to humans (22) and shares sequence homology even with some yeast cell-cycle genes (46) . On the other hand, the considerations that make improbable a relationship between ETS2 and AD may support ETS2 as a possible genetic element of an "ontogenetic" anomaly like DS. ETS2, as proposed for other oncogenes, might be critical for normal developmental processes. In this context, an overproduction of otherwise normal ETS2 proteins (27) could alter the delicate balance of biochemical pathways or could create interferences with cell-cell interaction processes necessary for a proper fetal development, thus causing some of the multiple abnormalities of DS. This hypothesis can be partially tested by introducing ETS2 in transgenic mice. Comparative human and murine genetic maps showed that ETS2 belongs to the group of genes on chromosome 21 that are present on mouse chromosome 16 (23, 47 (51) . These transgenic mice can be used to engineer mice carrying other human chromosome 21 genes, individually or in sets of two or more. From these animal models we should learn whether, indeed, an extra dosage of ETS2 is responsible for some of the major dismorphic features of DS, or whether it is simply predisposing to postnatal DS conditions like the increased susceptibility to leukemia (52) .
